iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing

News
- Oct 11
iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital
- Sep 5
iQ-007 Accepted into Prestigious NIH Preclinical Screening Platform for Pain (PSPP) Program
- Aug 21
iQure Pharma’s iQ-007 Completes Critical Go/No Go Criteria - September Start for MTD & GLP Tox Study
- Jul 5
iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy
- May 15
iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone
- Feb 24
iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results
- Nov 15, 2022
iQ-007 shows no abuse potential in FDA recommended panel of tests
- Sep 18, 2022
iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track
- Sep 8, 2022
iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry
- Mar 15, 2022
iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Neuropathic Pain
- Nov 5, 2021
Novel and promising mechanism of action for new neuropathic pain candidate iQ-007 confirmed
- May 25, 2021
iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)
- Sep 22, 2020
Preliminary Subchronic Toxicology Study Results Indicate iQ-007 Has Favorable Safety Profile
- Jan 23, 2020
iQ-007: Confirmation of Safety Profile and Second Indication by NINDS (US)